TransMedics Group's (TMDX) "Hold" Rating Reaffirmed at Needham & Company LLC

Key Points

• TransMedics Group's stock received a "hold" rating from Needham & Company, but several other analysts have recently issued higher price targets, with Oppenheimer increasing their target to $150.00.
• Shares of TransMedics Group fell by 2.5%, closing at $116.84, amid active trading with over 210,000 shares exchanged.
• The company reported a 37.7% year-over-year revenue increase, with a quarterly profit of $0.92 per share, surpassing analysts' expectations.

TransMedics Group (NASDAQ:TMDX - Get Free Report)'s stock had its "hold" rating reaffirmed by Needham & Company LLC in a research report issued to clients and investors on Monday,Benzinga reports.

Several other equities analysts have also recently issued reports on the stock. Canaccord Genuity Group boosted their price objective on shares of TransMedics Group from $129.00 to $142.00 and gave the company a "buy" rating in a research note on Tuesday, July 15th. Oppenheimer upped their price target on shares of TransMedics Group from $130.00 to $150.00 and gave the stock an "outperform" rating in a research note on Tuesday, June 17th. Piper Sandler reaffirmed an "overweight" rating and set a $145.00 price target (up from $125.00) on shares of TransMedics Group in a research note on Wednesday, June 4th. Wall Street Zen raised shares of TransMedics Group from a "hold" rating to a "buy" rating in a research note on Saturday, August 2nd. Finally, Morgan Stanley upped their price target on shares of TransMedics Group from $115.00 to $123.00 and gave the stock an "equal weight" rating in a research note on Friday, August 1st. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and three have issued a Hold rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $123.00.

TransMedics Group Stock Down 2.5%

Shares of TMDX stock traded down $3.0070 during trading on Monday, reaching $116.8430. The company's stock had a trading volume of 210,882 shares, compared to its average volume of 1,323,226. TransMedics Group has a 1-year low of $55.00 and a 1-year high of $177.00. The stock's 50-day moving average price is $121.65 and its 200 day moving average price is $101.70. The company has a debt-to-equity ratio of 1.61, a current ratio of 9.86 and a quick ratio of 9.17. The company has a market capitalization of $3.98 billion, a price-to-earnings ratio of 60.49 and a beta of 2.09.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last issued its quarterly earnings results on Wednesday, July 30th. The company reported $0.92 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.48 by $0.44. The company had revenue of $157.37 million during the quarter, compared to the consensus estimate of $146.64 million. TransMedics Group had a net margin of 13.49% and a return on equity of 28.02%. The firm's quarterly revenue was up 37.7% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.35 earnings per share. TransMedics Group has set its FY 2025 guidance at EPS. On average, research analysts anticipate that TransMedics Group will post 1 EPS for the current year.

Insider Buying and Selling

In related news, insider Anil P. Ranganath sold 686 shares of the stock in a transaction that occurred on Monday, June 9th. The shares were sold at an average price of $139.80, for a total transaction of $95,902.80. Following the completion of the sale, the insider owned 13,955 shares of the company's stock, valued at approximately $1,950,909. This represents a 4.69% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Edward M. Basile sold 5,000 shares of the stock in a transaction that occurred on Tuesday, May 27th. The stock was sold at an average price of $126.45, for a total transaction of $632,250.00. Following the sale, the director directly owned 2,866 shares of the company's stock, valued at approximately $362,405.70. This trade represents a 63.56% decrease in their position. The disclosure for this sale can be found here. 7.00% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On TransMedics Group

Several institutional investors and hedge funds have recently made changes to their positions in the business. Amalgamated Bank boosted its stake in shares of TransMedics Group by 0.8% during the 2nd quarter. Amalgamated Bank now owns 9,586 shares of the company's stock valued at $1,285,000 after buying an additional 80 shares during the last quarter. Canada Pension Plan Investment Board lifted its stake in TransMedics Group by 2.9% during the second quarter. Canada Pension Plan Investment Board now owns 3,600 shares of the company's stock worth $482,000 after purchasing an additional 100 shares during the last quarter. Smartleaf Asset Management LLC lifted its stake in TransMedics Group by 24.5% during the second quarter. Smartleaf Asset Management LLC now owns 548 shares of the company's stock worth $72,000 after purchasing an additional 108 shares during the last quarter. Ameritas Investment Partners Inc. lifted its stake in TransMedics Group by 4.4% during the second quarter. Ameritas Investment Partners Inc. now owns 3,394 shares of the company's stock worth $455,000 after purchasing an additional 142 shares during the last quarter. Finally, Franklin Resources Inc. lifted its stake in TransMedics Group by 1.0% during the second quarter. Franklin Resources Inc. now owns 14,842 shares of the company's stock worth $1,989,000 after purchasing an additional 148 shares during the last quarter. 99.67% of the stock is currently owned by hedge funds and other institutional investors.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.